Tamsulosin

Generic Name: Tamsulosin

Brand Names: Flomax, Jalyn

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈N_₂O_₅S

CAS Number: 106133-20-4

Unique Ingredient Identifier: G3P28OML5I

Background: Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.

Tamsulosin was first approved by the FDA on April 15, 1997.

Indication: Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.

Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.

Associated Conditions: Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus

Associated Therapies: -

Clinical Trials

Effect of Preoperative Tamsulosin on Postoperative Urinary Retention

Phase 3

Completed

Conditions: Postoperative Retention of Urine

Interventions: Drug: Placebo
Drug: Tamsulosin

First Posted Date: 2023-03-03

Last Posted Date: 2024-06-05

Lead Sponsor: NorthShore University HealthSystem

Target Recruit Count: 183

Registration Number: NCT05753670

Locations: 🇺🇸
NorthShore University Health System, Evanston, Illinois, United States

Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery

Early Phase 1

Recruiting

Conditions: Urinary Retention

Interventions: Drug: Tamsulosin

First Posted Date: 2022-12-20

Last Posted Date: 2024-10-31

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 46

Registration Number: NCT05657990

Locations: 🇺🇸
Ocean University Medical Center, Brick, New Jersey, United States
🇺🇸
South Ocean University Medical Center, Manahawkin, New Jersey, United States
🇺🇸
Jersey Shore University Medical Center, Neptune, New Jersey, United States

and more 1 locations

Silodosin vs Tamsulosin as MET

Phase 3

Recruiting

Conditions: Stone, Urinary

Interventions: Drug: Tamsulosin
Drug: Silodosin

First Posted Date: 2022-10-06

Last Posted Date: 2022-10-06

Lead Sponsor: Princess Margaret Hospital, Hong Kong

Target Recruit Count: 80

Registration Number: NCT05570084

Locations: 🇭🇰
Hong Kong, Hong Kong, Hong Kong

The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia

Phase 4

Recruiting

Conditions: Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms

Interventions: Drug: Silodosin Capsules
Drug: Tamsulosin
Drug: Ningmitai capsule

First Posted Date: 2022-09-22

Last Posted Date: 2022-09-23

Lead Sponsor: Xintian Pharmaceutical

Target Recruit Count: 312

Registration Number: NCT05551221

Locations: 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
🇨🇳
Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, China

and more 5 locations